Investor Centre
Our broad clinical and preclinical pipeline in brain disorders focuses on indications including addiction, anxiety, fatigue, narcolepsy and glioblastoma.
0.18 GBX
Volume:
103,598
Market Capitalisation (m)
£5.01
Diversified portfolio in high demand therapeutic areas
Diversified portfolio in high demand therapeutic areas
- Focus on brain disorders
- Pre-clinical CNS pipeline in indications with high unmet need – addiction, anxiety, narcolepsy
- Clinical stage, grant funded collaboration with Erasmus Medical Centre for SFX-01 in glioblastoma.
Significant market potential
Significant market potential
- Near clinic-ready CNS assets offer opportunity to build substantial value quickly
- Addiction market alone currently worth $40bn worldwide
- Out-licensing transactions at early and mid-stage development in the £00million range
- Lack of suitable drug candidates currently in development for addictive behaviours
Compelling data
Compelling data
- Heavily de-risked lead CNS programme – an Ox-1 inhibitor – with short path to key inflection point of clinical readiness
- Ox-1 antagonist (blocker) exhibits best-in-class potential
- DAT inhibitor candidate molecule at late preclinical stage targeting fatigue and narcolepsy
- High quality clinical and pre-clinical data on all assets, validated by third party experts
- Published in peer reviewed journals
Lead programmes funded to key inflection points
Lead programmes funded to key inflection points
- Ox-1 programme funded to clinical trial- readiness – allowing us to unlock potential commercial opportunities
- SFX-01 programme with Erasmus Medical Centre funded by KWF Dutch Cancer Society
- Cash runway to end 2026 – amongst the longest cash runways of UK and European listed biotech companies
- Capital efficient, virtual company with low overheads
Experienced leadership team
Experienced leadership team
- Leadership team brings extensive experience from across R&D, business development, biotech company building and successful exits
- Collectively delivered numerous biotech licensing deals and developed drugs to market
- Track record of effective company financing via both capital markets and non-dilutive grant funding
TheraCryf plc Investor Presentation
28 - September - 2026
TheraCryf shares the latest corporate presentation following announcement of the final results to end March 2026
Investor Meet Company - TheraCryf
28 - September - 2026IMC video following the announcement of TheraCryf's final results for the year ended 31 March 2026
TheraCryf plc Notice of AGM
30 - September - 2026Notice of AGM and Proxy form published ahead of TheraCryf's AGM on the 22nd October
Major Shareholders
| Current Shareholder | Number of shares | Percentage holding |
|---|---|---|
| Northern Standard Limited | 568,958,456 | 20.82% |
| First Equity Limited | 310,700,000 | 11.37% |
| T and I Limited | 160,000,000 | 5.86% |
| Hargreaves Lansdown Asset Management | 97,169,819 | 3.56% |
| Spreadex Limited | 80,050,001 | 2.93% |
| A Leach | 80,000,000 | 2.93% |
| S Gibeon | 71,400,000 | 2.61% |
| J. R. Kight | 70,000,000 | 2.56% |
| A J Bell Securities | 61,210,295 | 2.24% |
| P Byrne | 60,000,000 | 2.20% |
| K Byrne | 60,000,000 | 2.20% |
| TheraCryf plc Directors and Related Parties | 54,397,680 | 1.99% |
| Interactive Investor | 46,024,639 | 1.68% |
| N Burton | 40,000,000 | 1.46% |
| RAB Capital | 34,750,000 | 1.27% |
| N Hawkins | 30,000,000 | 1.10% |
| Charles Stanley (London) | 29,973,546 | 1.10% |
| Halifax Share Dealing | 29,507,221 | 1.08% |
| Barclay's Wealth (London) | 28,745,706 | 1.05% |
| Turner Pope Investments | 26,000,000 | 0.95% |
| C M Holmes | 25,500,000 | 0.93% |
| Peel Hunt | 24,928,854 | 0.91% |
| Octopus Investments | 21,875,000 | 0.80% |
| C G Poll | 21,500,000 | 0.79% |
| Rathbone Investment Management Ltd | 21,432,448 | 0.78% |
The number of ordinary shares in issue is 2,732,297,067. Directors hold 54,397,680 and 2,677,899,387 are in public hands. The Company does not hold any shares in the Treasury.
